Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13410176 | 1.00 | TGM2 (0.41) | TGM2SIRT5HTR2ASIRT2SIRT1 | |
| SCHEMBL30895569 | 0.94 | PTPN1 (0.45) | SIRT5HTR2APTPN1SSTR3 | |
| SCHEMBL16712824 | 0.94 | HTR2A (0.38) | TGM2SIRT5HTR2ASIRT2SIRT1 | |
| SCHEMBL13830646 | 0.94 | HTR2A (0.40) | SIRT5HTR2ASIRT2SIRT1SIRT3 | |
| SCHEMBL12944195 | 0.94 | HTR2A (0.40) | SIRT5HTR2ASIRT2SIRT1SIRT3 | |
| SCHEMBL12094377 | 0.94 | HTR2A (0.40) | SIRT5HTR2ASIRT2SIRT1SIRT3 | |
| SCHEMBL29579452 | 0.94 | HTR2A (0.40) | SIRT5HTR2ASIRT2SIRT1SIRT3 | |
| SCHEMBL2734925 | 0.94 | HTR2A (0.40) | SIRT5HTR2ASIRT2SIRT1SIRT3 | |
| SCHEMBL19731720 | 0.94 | HTR2A (0.40) | SIRT5HTR2ASIRT2SIRT1SIRT3 | |
| SCHEMBL29414597 | 0.94 | HTR2A (0.40) | SIRT5HTR2ASIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | CD47, ANTXR2, CD2BP2 | TGM2 772/4885SIRT5 1695/4885HTR2A 2993/4885 |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | CLSPN, CD74, ANTXR2 | TGM2 716/4885SIRT5 1087/4885HTR2A 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.